This report analyzes the worldwide markets for Colorectal Cancer Therapeutics in US$ Million. The major product segments analyzed are Cytotoxic Therapies (5-FU (Fluorouracil), Camptosar (Irinotecan), Eloxatin (Oxaliplatin), and Xeloda (Capecitabine), Targeted Therapies (Avastin (bevacizumab), and Erbitux (cetuximab). The report provides separate comprehensive analytics for the United States and Rest of World. Annual forecasts are provided for the period of 2001 through 2010. The report profiles 69 companies including many key and niche players worldwide such as Amgen Inc., Bristol-Myers Squibb, F.Hoffmann-La Roche Ltd., Genentech, Inc., Imclone Systems Inc., Novartis AG, Oxford Biomedica, Pfizer Inc., Sanofi-Aventis, and Schering AG. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

COLORECTAL CANCER THERAPEUTICS							MCP-1689
A GLOBAL STRATEGIC BUSINESS REPORT


                                             CONTENTS


  I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

      Study Reliability And Reporting Limitations                       I-1
      Disclaimers                                                       I-2
      Data Interpretation & Reporting Level                             I-2
       Quantitative Techniques & Analytics                              I-2
      Product Definitions And Scope Of Study                            I-3
       Cytotoxic Therapies                                              I-3
       Targeted Therapies                                               I-3


 II. EXECUTIVE SUMMARY

  1. Industry Overview                                                  II-1
      A Curtain Raiser                                                  II-1
       Table 1: New Cases of Colorectal Cancer Diagnosed  in the US
       for 2003-2006 (includes corresponding Graph/Chart)               II-1

       Table 2: Mortality Due to Colorectal Cancer in North  America
       (2000-2003)-Breakdown by Region-United  States, Canada and
       Mexico (includes  corresponding Graph/Chart)                     II-2

       Table 3: Mortality Due to Colorectal Cancer in Latin  America
       (2000-2003)-Breakdown by Region-Brazil, Argentina, Venezuela,
       Peru, and Chile (includes corresponding Graph/Chart)             II-2

       Table 4: Mortality Due to Colorectal Cancer in Asia-Pacific
       (2000-2003)-Breakdown by Region-China, Japan, India,
       Indonesia, Philippines, Australia, Thailand, South Korea,
       Malaysia, Hong Kong, New Zealand, Singapore  and Taiwan
       (includes corresponding Graph/Chart)                             II-3

       Table 5: Mortality Due to Colorectal Cancer in Western Europe
       (2000-2003)-Breakdown by Region-Belgium,  Austria, Denmark
       and Finland (includes  corresponding Graph/Chart)                II-3

       Table 6: Staged Incidence of Cancer in the US by
       Race/Ethnicity: (1992-2000) (includes  corresponding
       Graph/Chart)                                                     II-4
      Why Screening Rate is Low in Colorectal Cancer?                   II-4
       Strategies to Increase Screening Rate                            II-5
      Early Screening & Detection- A Antidotes to Beat  the Odds        II-5
       Test at Home                                                     II-5
        Breakdown of Colorectal Cancer Cases Based on  the Risk
         Category                                                       II-6
        Guidelines for Screening & Surveillance For  Early Detection
         of Colorectal Cancer                                           II-6
      Who is at a Greater Risk of Developing Colorectal  Cancer?        II-7
       Genetic Disposition                                              II-7
        Table 7: Selected Risk Factors and their Relative Risk
        Percentage in Colorectal Cancer (includes  corresponding
        Graph/Chart)                                                    II-7
      Happy Days are Here Again                                         II-8
       Table 8: Five Year Disease -Free Survival Rate of Various
       Cancers by Type- Colorectal Cancer, Cervical Cancer, Ovarian
       Cancer, Breast Cancer, and Malignant  Melanoma (includes
       corresponding Graph/Chart)                                       II-8
       An Insight into Colorectal Cancer Therapeutic  Alternatives      II-9

  2. Market Pulse                                                       II-10
      Is Huge Cost of Drugs a Major Concern?                            II-10
       Price Comparisons Among Leading Cancer Drugs  Currently
        Available                                                       II-10
      Is Cytotoxic Therapy Heading Towards the Sunset?                  II-10
       An Insight into Cytotoxic Drugs Available in the US
        Colorectal Cancer Market                                        II-11
       Expiry Period of Leading Cytotoxic Drugs-  Camptosar,
        Eloxatin, and Xeloda                                            II-11
       5-FU Struggling to Hold Share                                    II-11
       Xeloda on a Rise with Growing Indications                        II-11
        Ongoing Phase III Clinical Trials to Evaluate Efficacy  of
         Xeloda in Colorectal Cancer                                    II-12
       Edotecarin-An Evolving Cytotoxic Therapy                         II-12
      Targeted Therapies-All Set to Stake a Claim Over the  Future      II-12
       Avastin- The Wonder Drug                                         II-13
       Table 9: Key Parameters that Promote use of Avastin (includes
        corresponding Graph/Chart)                                      II-13
       PTK787 (vatalanib)                                               II-13
       ABX-EGF                                                          II-14
       Targeted Therapies Add Value to Treatment Strategies             II-14
       Panitumumab- A Key Contender to Erbitux                          II-14
       PTK787 v/s Avastin- Serious Warfare                              II-15
      Combination Therapy- Offering a Lucrative Option                  II-15
       A Peek into Standard Combination Therapies in  Colorectal
        Cancer and their Status                                         II-15
      Reoccurrence of Cancer -A Prime Concern                           II-16
       Table 10: Revenues from Adjuvant Colorectal Cancer Therapies
       in the US 2004-2007 (In US$ Million)  (includes corresponding
       Graph/Chart)                                                     II-16

       Table 11: Number of Colorectal Cancer Patients in  Adjuvant
       Settings in the US: 2001-2007 (includes corresponding
       Graph/Chart)                                                     II-16
       Adjuvant Therapy in Colon Cancer                                 II-17
       Adjuvant Therapy in Rectal Cancer                                II-17
        Colorectal Cancer Drugs in Adjuvant Settings                    II-17

  3. Clinical Trials                                                    II-18
      Prominent Products Still in Pipeline                              II-18
       A Snapshot of Potential Drugs in the Pipeline                    II-18

  4. Clinical Studies                                                   II-20
      Adapalene (CD271) Retinoid Agent Induces Apoptosis  in Colon
       Cancer Cells                                                     II-20
      Laparoscopic Surgery Vs Open Surgery                              II-20
      Discontinuation of Chemotherapy Drugs Raises the  Chances of
       Reoccurrence                                                     II-20
      Colorectal Cancer and Natural Substances                          II-20
       Magnesium                                                        II-20
       Vitamin D Protects Development of Tumor in Colon                 II-21
       High Intake of Vitamin B Reduces Risk in Women                   II-21
       Diet Rich in Flavonoids Fights Well Against  Colorectal Cancer   II-21
      Colorectal Cancer and Other Medications                           II-21
       NSAIDs Reduce the Risk of Colorectal Cancer                      II-21
       Efficacy of Cancer Vaccine, ALVAC-CEA/B7.1,  in Colorectal
        Cancer                                                          II-21
       Insulin Therapy in type 2 Diabetic Patients  Increases Risk      II-22

  5. Product Overview                                                   II-23
      Colorectal Cancer-An Insight                                      II-23
       Colorectal Cancer . What is it .!!!                              II-23
       What are the Symptoms?                                           II-23
       Risk Factors                                                     II-24
        Selected General Risk Factors and their Relative  Risk Rate
         in Colorectal Cancer                                           II-24
       Screening and Treatment                                          II-25
        Screening Options                                               II-25
         Digital Rectal Examination (DRE)                               II-25
         Fecal Occult Blood Test                                        II-25
         Flexible Sigmoidoscopy                                         II-25
         Barium Enema                                                   II-25
         Colonoscopy                                                    II-25
        Additional Screening Options Of Recent Origin                   II-25
         DNA-based Stool Test                                           II-25
         Virtual Colonoscopy                                            II-26
          A Comparative Analysis of Various Colorectal Cancer
           Screening Options Based on Parameters Such as
            Complexity, Risk Element, Potential Effectiveness,
             Overall Performance and Significant  Limitations           II-26
          Appropriate Time Frame for Screening and  Surveillance of
           Colorectal Cancer for Both  Women and Men in the Age
            Group  of 50 or More                                        II-26
       Supportive Diagnostic Tests                                      II-27
       Diagnosis/Treatment Options                                      II-27
        Partial Colectomy                                               II-27
        Chemotherapy                                                    II-27
        Surgery                                                         II-27
        Radiation Therapy                                               II-27
         A Structural Analysis of Available Treatment  Options in
          Colorectal Cancer                                             II-28
       Staging                                                          II-28
       Colorectal Cancer Therapies-At a Glance                          II-29
        Cytotoxic Therapies                                             II-29
         5-FU (Fluorouracil)                                            II-29
         Camptosar (Irinotecan)                                         II-29
         Eloxatin (Oxaliplatin)                                         II-29
         Xeloda (Capecitabine)                                          II-30
        Targeted Therapies                                              II-30
         Angiogenesis Pathway                                           II-30
          Avastin (bevacizumab)                                         II-31
         EGF Pathway                                                    II-31
          Erbitux (cetuximab)                                           II-31
         Cell Proliferation/Apoptosis                                   II-32
         Immune Response                                                II-32
          Cancer Vaccines                                               II-32
          Monoclonal Antibodies & their Function                        II-32
           An Insight into the Targeted Therapies                       II-33
           A Synoptic Review of Available Drugs Indicated  in
            Treating Colorectal Cancer                                  II-33

  6. Product Approvals /Launches                                        II-34
      Chugai Applies for Quick Approval of Avastin in Japan             II-34
      Genentech Obtains FDA Approval for Avastin in  Combination
       Therapy                                                          II-34
      US FDA Approves Adjuvant Status for Roche's  Oral Xeloda          II-34
      Antisoma's AS 1404 and Avastin Combination Therapy  Proves
       Effective in Colon and Lung Cancer                               II-35
      ImClone Systems and Bristol-Myers Squibb Receive  Approval for
       Erbitux Injection                                               II-35
      John Hopkins Develops Colorectal Cancer Blood Test  Jointly
       with Howard Hughes Medical Institute  and Indivumed              II-35
      Genentech Receives FDA Approval for Avastin                       II-35
      Oxford BioMedica Gains Approval for Phase II  Trial of TroVax    II-36
      Roche's Xeloda Gets Clearance as First-Line Colorectal  Cancer
       Treatment                                                        II-36
      LabCorp Introduces DNA-based Colorectal Cancer Test               II-36

  7. Recent Industry Activity                                           II-37
      Amgen Acquires Abgenix                                            II-37
      Chiron Merges with Novartis                                       II-37
      Bayer to Acquire Schering AG                                      II-37
      Biosite Collaborates with Oxford Genome                           II-37
      Medarex Collaborates with Oxford Genome Sciences                  II-37
      Pharmexa Acquires GemVax                                          II-38
      AstraZeneca to Acquire KuDOS Pharmaceuticals                      II-38
      Aphton Corporation Acquires Igeneon                               II-38
      IDM S.A. and Epimmune Merge to Form IDM Pharma                    II-38
      Hybridon Renamed as Idera Pharmaceuticals                         II-38
      Merck KGaA Acquires Rights for Taiho  Pharmaceutical's UFT        II-38
      Novartis and Schering Co-Promote PTK787/ZK 222584  Cancer Drug    II-38
      TWTI and Genzyme Genetics Set Up a Marketing  Association         II-39
      Callisto Receives Patent for its Colon Cancer Drug                II-39
      Amgen and Abgenix Receive FDA Approval for  Panitumumab in
       Metastatic Colorectal Cancer                                     II-39
      ADVENTRX Receives MHRA Approval to Initiate  Phase IIb
       Clinical Trial                                                   II-39
      Sanofi Acquires Aventis to Form Sanofi-Aventis                    II-39

  8. Focus on Select Players                                            II-40
      Amgen Inc. (USA)                                                  II-40
      Bristol-Myers Squibb (USA)                                        II-40
      F.Hoffmann-La Roche Ltd. (Switzerland)                            II-40
      Genentech, Inc. (USA)                                             II-40
      Imclone Systems Inc. (USA)                                        II-41
      Novartis AG (Switzerland)                                         II-41
      Oxford Biomedica (UK)                                             II-41
      Pfizer Inc. (USA)                                                 II-41
      Sanofi-Aventis (France)                                           II-42
      Schering AG (Germany)                                             II-42

  9. Global Market Perspective                                          II-43
      Table 12: World Recent Past, Current & Future Analysis  for
      Colorectal Cancer Therapeutics by Geographic Region/Country -
      United States and Rest of World  Markets Independently
      Analyzed with Annual Sales  in US$ Million for Years 2001
      through 2010  (includes corresponding Graph/Chart)                II-43

      Table 13: World 10-Year Perspective for Colorectal  Cancer
      Therapies by Geographic Region/Country -  Percentage Breakdown
      of Dollar Sales for  United States and Rest of World for Years
      2001, 2006 and 2010                                               II-43

      Table 14: World Recent Past, Current & Future Analysis for
      Cytotoxic Therapies for Colorectal Cancer by Geographic
      Region/Country - United States and Rest of World Markets
      Independently Analyzed with Annual Sales in US$  Million for
      Years 2001 through 2010 (includes  corresponding Graph/Chart)     II-44

      Table 15: World 10-Year Perspective for Cytotoxic  Therapies
      for Colorectal Cancer by Geographic Region/ Country -
      Percentage Breakdown of Dollar Sales  for United States and
      Rest of World for  Years 2001, 2006 and 2010                      II-44

      Table 16: World Recent Past, Current & Future Analysis for
      Camptosar in Colorectal Cancer by Geographic Region/ Country -
      United States and Rest of World Markets Independently Analyzed
      with Annual Sales in US$  Million for Years 2001 through 2010
      (includes  corresponding Graph/Chart)                             II-45

      Table 17: World 10-Year Perspective for Camptosar  in
      Colorectal Cancer by Geographic Region/ Country - Percentage
      Breakdown of Dollar Sales  for United States and Rest of World
      for Years  2001, 2006 and 2010                                    II-45

      Table 18: World Recent Past, Current & Future Analysis for
      Eloxatin in Colorectal Cancer by Geographic Region/ Country -
      United States and Rest of World Markets Independently Analyzed
      with Annual Sales in US$  Million for Years 2001 through 2010
      (includes  corresponding Graph/Chart)                             II-46

      Table 19: World 10-Year Perspective for Eloxatin  in
      Colorectal Cancer by Geographic Region/ Country - Percentage
      Breakdown of Dollar Sales  for United States and Rest of World
      for Years  2001, 2006 and 2010                                    II-46

      Table 20: World Recent Past, Current & Future Analysis for
      Xeloda in Colorectal Cancer by Geographic Region/Country -
      United States and Rest of World Markets Independently Analyzed
      with Annual Sales in US$ Million for Years  2001 through 2010
      (includes corresponding graph/chart)                              II-47

      Table 21: World 10-Year Perspective for Xeloda in Colorectal
      Cancer by Geographic Region/Country - Percentage  Breakdown of
      Dollar Sales for United States and Rest  of World for Years
      2001, 2006 and 2010                                               II-47

      Table 22: World Recent Past, Current & Future Analysis  for
      Targeted Therapies for Colorectal Cancer by  Geographic
      Region/Country - United States and  Rest of World Markets
      Independently Analyzed with  Annual Sales in US$ Million for
      Years 2004 through  2010 (includes corresponding graph/chart)     II-48

      Table 23: World 6-Year Perspective for Targeted Therapies  for
      Colorectal Cancer by Geographic Region/Country - Percentage
      Breakdown of Dollar Sales for United States  and Rest of World
      for Years 2004, 2006 and 2010                                     II-48

      Table 24: World Recent Past, Current & Future Analysis  for
      Avastin in Colorectal Cancer by Geographic Region/ Country -
      United States and Rest of World Markets Independently Analyzed
      with Annual Sales in  US$ Million for Years 2004 through 2010
      (includes corresponding graph/chart)                              II-49

      Table 25: World 6-Year Perspective for Avastin in Colorectal
      Cancer by Geographic Region/Country - Percentage  Breakdown of
      Dollar Sales for United States and Rest  of World for Years
      2004, 2006 and 2010                                               II-49

      Table 26: World Recent Past, Current & Future Analysis for
      Erbitux in Colorectal Cancer by Geographic Region/ Country -
      United States and Rest of World Markets Independently Analyzed
      with Annual Sales in US$  Million for Years 2004 through 2010
      (includes  corresponding graph/chart)                             II-50

      Table 27: World 6-Year Perspective for Erbitux in  Colorectal
      Cancer by Geographic Region/Country -  Percentage Breakdown of
      Dollar Sales for United  States and Rest of World for Years
      2004,  2006 and 2010                                              II-50


III. MARKET

  1. US                                                                 III-1
      A.Market Analysis                                                 III-1
        Introduction                                                    III-1
         Market Accelerators                                            III-1
         Market Challenges                                              III-1
         Market Inhibitors                                              III-1
        Why Cost of Cancer Drugs is Too High in the US?                 III-1
        Free-market Healthcare System- "For" & "Against"                III-2
        Erbitux- Making a Way Through the Colorectal  Cancer Market     III-2
         Erbitux-A Blockbuster Drug in Third-Line  Therapy              III-2
         Erbitux Enters the Genre of Second-Line  Therapies             III-3
        Who Leads the Pack?                                             III-3
         Sanofi-Aventis- The Clear Leader                               III-3
          Table 28: US Colorectal Cancer Market (2004): Percentage
          Breakdown of Leading Players-Sanofi-Aventis, Genentech,
          Pfizer, ImClone Systems/Bristol Myers-Squibb, Roche, and
          Generic Manufacturers-Ranked by Revenue (includes
          corresponding Graph/Chart)                                    III-3

          Table 29: US Colorectal Cancer Market for Cytotoxic
          Therapies (2004): Percentage Breakdown of Leading
          Players-Sanofi-Aventis, Pfizer, Roche and Generic
          Manufacturers-Ranked by Revenue (includes corresponding
          Graph/Chart)                                                  III-4

          Table 30: US Colorectal Cancer Market for Targeted
          Therapies (2004): Percentage Breakdown of Leading
          Players-Genentech and ImClone Systems/Bristol
          Myers-Squibb-Ranked by Revenues                               III-4
        Crucial Statistics                                              III-4
         Table 31: Incidence of Colorectal Cancer in the US
         (2006)-Breakdown by Stages (includes  corresponding
         Graph/Chart)                                                   III-4

         Table 32: US Colorectal Cancer Statistics  for 2004 & 2003
         (includes corresponding  Graph/Chart)                          III-4

         Table 33: New Cases of Colorectal Cancer in the  US for the
         years 2005 & 2006-Breakdown  by Cancer Type                    III-5

         Table 34: New Colorectal Cancer Cases in the US  in 2004 &
         2003-Breakdown by Type & Gender                                III-5
        Product Approvals/Launches                                      III-5
        Strategic Developments                                          III-7
        Focus on Select Players                                         III-8
      B.Market Analytics                                                III-9
        Table 35: US Recent Past, Current & Future Analysis For
        Colorectal Cancer Therapeutics By Product Segments-
        Cytotoxic Therapies (5-Fu, Camptosar, Eloxatin And Xeloda)
        And Targeted Therapies (Avastin And Erbitux) Markets
        Independently Analyzed With Annual Sales  In Us$ Million For
        Years 2001 Through 2010  (includes corresponding
        Graph/Chart)                                                    III-9

        Table 36: US 10-Year Perspective For Colorectal  Cancer
        Therapeutics By Product Segments - Percentage  Breakdown Of
        Dollar Sales For Cytotoxic Therapies  (5-Fu, Camptosar,
        Eloxatin And Xeloda) And  Targeted Therapies (Avastin And
        Erbitux)  For Years 2001, 2006 And 2010 (includes
        corresponding Graph/Chart)                                      III-10

  2. Rest of World                                                      III-11
      A.Market Analysis                                                 III-11
        Focus on Select Countries                                       III-11
        Canada                                                          III-11
         Incidence                                                      III-11
         Vital Statistics                                               III-11
          Table 37: Canadian Cancer Market (2005): Percentage
          Breakdown of New Cancer Cases Among Men  (includes
          corresponding Graph/Chart)                                    III-11

          Table 38: Canadian Cancer Market (2005): Percentage
          Breakdown of Cancer Mortality Among Men  (includes
          corresponding Graph/Chart)                                    III-11

          Table 39: Canadian Cancer Market (2005): Percentage
          Breakdown of New Cancer Cases Among Women (includes
          corresponding Graph/Chart)                                    III-11

          Table 40: Canadian Cancer Market (2005): Percentage
          Breakdown of Cancer Mortality Among Women (includes
          corresponding Graph/Chart)                                    III-12

          Table 41: New Colorectal Cancer Cases in  Canada in 2005-
          By Gender                                                     III-12

          Table 42: New Colorectal Cancer Cases in Canada  in
          2005-Breakdown By Age Group (includes corresponding
          Graph/Chart)                                                  III-12

          Table 43: Colorectal Cancer Mortality Statistics  in
          Canada in 2005-Ranked By Gender                               III-12

          Table 44: Colorectal Cancer Mortality Statistics  in
          Canada in 2005-Breakdown By Age Group  (includes
          corresponding Graph/Chart)                                    III-13

          Table 45: Incidence of Colorectal Cancer Among  Men in
          Canada-By Region: 2005 (includes corresponding
          Graph/Chart)                                                  III-13
          Table 46: Incidence of Colorectal Cancer Among Women in
           Canada-By Region: 2005 (includes corresponding Graph/
            Chart)                                                      III-13
        Finland                                                         III-14
         Overview                                                       III-14
         Active Screening Programs- A Mission to Fight  Against Cancer  III-14
        Product Approvals                                               III-14
        Strategic Developments                                          III-15
        Focus on Select Players                                         III-17
      B.Market Analytics                                                III-19
        Table 47: Rest of World Recent Past, Current & Future
        Analysis for Colorectal Cancer Therapeutics by Product
        Segments- Cytotoxic Therapies (Camptosar, Eloxatin and
        Xeloda) and Targeted Therapies (Avastin and Erbitux) Markets
        Independently Analyzed with Annual Sales  in US$ Million for
        Years 2001 through 2010  (includes corresponding
        Graph/Chart)                                                    III-19

        Table 48: Rest of World 10-Year Perspective for  Colorectal
        Cancer Therapeutics by Product Segments - Percentage
        Breakdown of Dollar Sales for Cytotoxic Therapies
        (Camptosar, Eloxatin and Xeloda) and  Targeted Therapies
        (Avastin and Erbitux)  for Years 2001, 2006 and 2010
        (includes  corresponding Graph/Chart)                           III-19


 IV. COMPETITIVE LANDSCAPE